We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/11/2014 12:38 | looks an interesting company. Good to see the options don't kick in till the sp>27p, or eps>1p, very encouraging. | the prophet | |
24/11/2014 12:19 | Collagen Solutions PLC 24 November 2014 Collagen Solutions Plc (the "Company" or the "Group") Grant of Option Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce that it has today granted an option to Gillian Black, Chief Financial Officer, over up to 1,000,000 new ordinary shares of one penny each in the Company ("Ordinary Shares") pursuant to the terms of the EMI Share Option Scheme ("Option") exercisable at a price of 7.75p. The Option will become exercisable from 1 January 2017 subject to Ms Black remaining in employment with the Company (or any other member of the Company's Group) and the achievement of either of the following two targets: 1) the market value of an Ordinary Share being equal to or greater than 27p on any date after the date of grant; and 2) the Company's earnings per share in any financial year which ends after the date of grant being equal to or greater than 1p. Following the grant of the Option, the total number of options outstanding over Ordinary Shares is 5,938,349 equivalent to 9.30% of the Company's existing issued share capital. | doodlebug4 | |
24/11/2014 08:46 | Got in on cos today, interesting share, I have an interest in collagen products for a while, with medical benefits and mankind's obsession with rejuvenation this could be a multiple bagger. Time will tell, but seem to be getting an excellent business structure in place | jacobjohn7 | |
21/11/2014 17:30 | Small investment here today :) | tpau | |
21/10/2014 11:22 | Interview: Stewart White, Collagen Solutions on TSB SMART Award - YouTube Oct 21, 2014 | jane downs | |
10/6/2014 09:21 | Collagen Solutions signs exclusive licence StockMarketWire.com Collagen Solutions has announced the exclusive licensing of intellectual property generated in the laboratory of Professor Robert Brown at University College London (UCL). The core patent, already granted in the US, describes a breakthrough platform technology for the production of stronger, more durable, living collagen-based 'tissues'. Using the novel process covered by the licence, the production process creates collagen materials with a significant range of additional clinical applications in the replacement of tissues such as skin, tendon, bone and even cartilage, blood vessels and nerve conduits. The most significant advantage of these natural, living materials are their physical strength and rapid production times. This means that surgeons will be able to implant them sooner, whilst at the same time, there is the potential to have the novel collagen-based products customised to the precise needs of the patient and their injury. From a business and manufacturing perspective, there is also the advantage that the collagen sources used for these materials are many times more efficient than current comparable collagen feed-stocks. These advantages will inevitably assist other areas of clinical research into technologies for rapid and specific fabrication of novel tissues using bio-lamination or 3D bio-printing which are presently very difficult due to the lack of suitable support materials. It is envisaged that this platform technology will enable the creation of a new generation of collagen based tissue replacements for use in a far wider patient population than is presently feasible with added potential to expedite both autologous and allogeneic cell therapies. Chief executive Dr Stewart White said: "This licence is hugely significant for Collagen Solutions as it places us at the very centre of the future of collagen engineering. "With our own know-how and exclusive access to the technology developed in Professor Brown's laboratory, we believe that this combination will make us the 'go to' company for any company looking to create biomaterial-based tissue regeneration and repair products. The licensing of this IP is designed to integrate our specialist collagen capabilities with the diverse biomedical capacity and global research standing of UCL and will drive forward patient benefit in many new areas of regenerative medicine." | doodlebug4 | |
06/1/2014 11:07 | Interesting stock | imponderabilia | |
06/1/2014 11:06 | Thank you for starting this thread, cnx - appreciated. | doodlebug4 | |
20/5/2009 02:37 | Sorry, can't access the charts from ADVFN for the above reason - on setting up the thread, the EPIC box doesn't accept the full COS.UN. Traded on the TSX. | nil pd | |
20/5/2009 02:33 | Will this work?! The EPIC box won't let me type COS.UN in full...no, doesn't work. Canadian Oil Sands Trust provides a pure investment opportunity in the oil sands through its 36.74% interest in the Syncrude Project. Syncrude is a leader in Canada's oil sands industry, operating since 1978 with a productive capacity today of 350,000 barrels per day of light, high-quality crude oil. Structured as an income trust, Canadian Oil Sands has approximately 483 million units outstanding, and trades on the Toronto Stock Exchange under the symbol COS.UN. Syncrude Project Syncrude is a leader in Canada's oil sands industry with a productive capacity equivalent to over 15% of the nation's crude oil requirements. The Syncrude project is a joint venture undertaking among 7 participants. Syncrude ownership: Canadian Oil Sands Limited (36.74%); Conoco-Phillips Oil Sand Partnership II (9.03%); Imperial Oil Resources (25%); Mocal Energy Limited (5%); Murphy Oil Company Ltd. (5%); Nexen Oil Sands Partnership (7.23%); and Petro-Canada Oil and Gas (12%). Operator: Syncrude Canada Ltd. operates and .... for more go to: | nil pd | |
22/9/2008 00:03 | Sign by Danasoft - | fatgreek | |
14/8/2008 21:30 | Hi Robo, not in CHP at the mo, bought a shed load in IVE at the moment, how about you? | fatgreek | |
25/7/2008 20:58 | FG, Now I know where to come for some good images when MRP rocket's. Lol Have you bought back into chp? | robo63 | |
25/7/2008 19:35 | just thought I'd let you guys know if you're looking for a date, go to , its my dating website | fatgreek |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions